within Pharmacolibrary.Drugs.ATC.J;

model J07BB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.0,
    adminDuration  = 600,
    adminMass      = 0.015,
    adminCount     = 1,
    Vd             = 0,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Influenza, inactivated, split virus or surface antigen vaccines are used to prevent influenza (flu) caused by influenza viruses. These vaccines contain inactivated (killed) influenza viruses and are often split or contain only the surface antigens to minimize side effects. They are administered annually and are approved for use in most countries for the prevention of seasonal influenza.</p><h4>Pharmacokinetics</h4><p>No direct pharmacokinetic data published for inactivated, split virus or surface antigen influenza vaccines in humans. As these are vaccines, they are not absorbed, distributed, metabolized, or eliminated in the same way as traditional small-molecule drugs; rather, they elicit an immune response at the injection site.</p><h4>References</h4><ol><li><p>Kim, YH, et al., &amp; Nam, JH (2022). Influenza vaccines: Past, present, and future. <i>Reviews in medical virology</i> 32(1) e2243–None. DOI:<a href=&quot;https://doi.org/10.1002/rmv.2243&quot;>10.1002/rmv.2243</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33949021/&quot;>https://pubmed.ncbi.nlm.nih.gov/33949021</a></p></li><li><p>Chen, J, et al., &amp; Ly, H (2021). Advances in Development and Application of Influenza Vaccines. <i>Frontiers in immunology</i> 12 711997–None. DOI:<a href=&quot;https://doi.org/10.3389/fimmu.2021.711997&quot;>10.3389/fimmu.2021.711997</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34326849/&quot;>https://pubmed.ncbi.nlm.nih.gov/34326849</a></p></li><li><p>Cowling, BJ, &amp; Okoli, GN (2024). Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine. <i>Drugs</i> 84(9) 1013–1023. DOI:<a href=&quot;https://doi.org/10.1007/s40265-024-02083-8&quot;>10.1007/s40265-024-02083-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39167316/&quot;>https://pubmed.ncbi.nlm.nih.gov/39167316</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end J07BB02;
